MPO and obesity due to melanocortin 4 receptor deficiency: Thus, future studies should evaluate the beneficial effects of targeting MPO and ANGPTL6 simultaneously for the treatment of both obesity and T2D by inhibiting the activity of MPO and overexpression of ANGPTL6.